Sean Laaman

Stock Analyst at Morgan Stanley

(2.62)

# 2,132

Out of 4,711 analysts

2

Total ratings

50%

Success rate

33.19%

Average return

Main Sectors:

Top Industries:

Biotechnology Medical Instruments & Supplies

Stocks Rated by Sean Laaman

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	BGNE BeiGene	Assumes: Overweight	$300	$176.50	+69.97%	1	Dec 3, 2024
	RMD ResMed	Upgrades: Overweight	$169	$237.27	-28.77%	1	Oct 27, 2023

BeiGene

Dec 3, 2024

Assumes: Overweight

Price Target: $300

Current: $176.50

Upside: +69.97%

ResMed

Oct 27, 2023

Upgrades: Overweight

Price Target: $169

Current: $237.27

Upside: -28.77%